Rapp 2018.
Study name | GlioVax |
Starting date | March 2018 |
Contact information | Michael Sabel (Michael.Sabel@med.uni‐duesseldorf.de) |
Notes | Trial identifier: EudraCT‐Number 2017–000304‐14 Country: Germany Inclusion criteria: monofocal GBM, IDH wild‐type; near‐complete resection (≤ 5 mL residual tumour volume); Karnofsky performance status ≥ 70% |
GBM: glioblastoma; IDH: isocitrate dehydrogenase.